| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| O Gosselin, J M Ribeyre, J P Kah. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine]. L'Encephale. vol 23 Spec No 4. 1997-12-30. PMID:9417400. |
first, identifying the action sites, in the brain, specific to clozapine and to conventional neuroleptics, in order to classify those drugs on the basis of the observed differences in pharmacoclinical profile (low incidence of neurological side effects, activity on schizophrenic deficiency symptoms, activity vis-à-vis certain forms of recalcitrant schizophrenia). |
1997-12-30 |
2023-08-12 |
Not clear |
| A S Brown, G Gewirtz, J Harkavy-Friedman, T Cooper, G Brébion, X F Amador, D Malaspina, J M Gorma. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 17. issue 5. 1997-12-22. PMID:9348547. |
effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. |
1997-12-22 |
2023-08-12 |
human |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
should clozapine be a first-line treatment for schizophrenia? |
1997-12-19 |
2023-08-12 |
Not clear |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
recent studies suggest that clozapine is more effective than typical neuroleptics for patients with treatment-resistant schizophrenia. |
1997-12-19 |
2023-08-12 |
Not clear |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
the hypothesis behind this article, however, is that clozapine may not only be more effective than typical neuroleptics for individuals with "first-episode" schizophrenia but may also lead to a better long-term course in such patients. |
1997-12-19 |
2023-08-12 |
Not clear |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
when examined in light of wyatt's recent proposal that each period of symptom exacerbation may lay the groundwork for further symptoms and for increasing syndrome severity, the data suggest that clozapine, despite its disturbing side-effect profile, should be studied in controlled double-blind clinical trials during patients' first episode of schizophrenia. |
1997-12-19 |
2023-08-12 |
Not clear |
| A I Green, J J Schildkrau. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard review of psychiatry. vol 3. issue 1. 1997-12-19. PMID:9384923. |
if such investigations show that clozapine is more effective than typical neuroleptics for patients with first-episode schizophrenia and results in a better long-term course, then its benefits and risk as a routine first-line treatment for schizophrenia can be considered. |
1997-12-19 |
2023-08-12 |
Not clear |
| R R Conley, R W Buchana. Evaluation of treatment-resistant schizophrenia. Schizophrenia bulletin. vol 23. issue 4. 1997-12-16. PMID:9366002. |
a systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of clozapine, risperidone, and olanzapine. |
1997-12-16 |
2023-08-12 |
Not clear |
| R Gutierrez-Esteinou, J A Greb. Risperidone: an analysis of the first three years in general use. International clinical psychopharmacology. vol 12 Suppl 4. 1997-12-10. PMID:9352340. |
in addition, a prospective comparison with risperidone and clozapine and a subanalysis of the north american trial of risperidone show that risperidone is effective in treatment-resistant schizophrenia. |
1997-12-10 |
2023-08-12 |
Not clear |
| M Herma. Clinical response to clozapine treatment of 11 chronic patients in a state psychiatric hospital. The Australian and New Zealand journal of mental health nursing. vol 6. issue 3. 1997-12-04. PMID:9384012. |
the aim of this study was to evaluate the clinical response to clozapine of 11 treatment-resistant patients with schizophrenia. |
1997-12-04 |
2023-08-12 |
Not clear |
| W Retz, M Rösler, L Sitzmann, T Becke. [Clozapine in treatment of neuropsychiatric diseases in the elderly]. Fortschritte der Neurologie-Psychiatrie. vol 65. issue 8. 1997-11-07. PMID:9378447. |
there are some studies and reports available about clozapine in the treatment of psychosis in patients suffering from dementia, schizophrenia and parkinson's disease, which are reported here. |
1997-11-07 |
2023-08-12 |
Not clear |
| C J Hong, Y L Lee, C B Sim, H G Hw. Dopamine D4 receptor variants in Chinese sporadic and familial schizophrenics. American journal of medical genetics. vol 74. issue 4. 1997-11-06. PMID:9259377. |
the number of repetitions of the 48bp unit was shown to influence the binding of clozapine, which suggests that different alleles may function differently in vivo and affect the pathogenesis of schizophrenia. |
1997-11-06 |
2023-08-12 |
Not clear |
| I Leykin, R Mayer, M Shinitzk. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology. vol 37. issue 1. 1997-10-29. PMID:9285246. |
in line with the autoimmune hypothesis of schizophrenia we have tested in this study whether the commonly used neuroleptics, clozapine and haloperidol can also act as systemic immunosuppressants. |
1997-10-29 |
2023-08-12 |
mouse |
| M Turetz, T Mozes, P Toren, N Chernauzan, R Yoran-Hegesh, R Mester, N Wittenberg, S Tyano, A Weizma. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. The British journal of psychiatry : the journal of mental science. vol 170. 1997-10-28. PMID:9330014. |
an open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. |
1997-10-28 |
2023-08-12 |
Not clear |
| S Sanyal, H H Van To. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. Journal of psychiatric research. vol 31. issue 2. 1997-10-23. PMID:9278187. |
the observations which support the idea that d4 might serve as a target for clozapine have significantly modified and extended our understanding of mechanisms underlying atypical antipsychotic treatment of schizophrenia, as well as the dopamine hypothesis for schizophrenia. |
1997-10-23 |
2023-08-12 |
Not clear |
| H Weigmann, J Bierbrauer, S Härtter, C Hiemk. Automated determination of clozapine and major metabolites in serum and urine. Therapeutic drug monitoring. vol 19. issue 4. 1997-09-29. PMID:9263393. |
clozapine is an atypical neuroleptic that is increasingly used for the treatment of schizophrenia. |
1997-09-29 |
2023-08-12 |
human |
| W H Chang, S K Lin, H Y Lane, W H Hu, M W Jann, H N Li. Clozapine dosages and plasma drug concentrations. Journal of the Formosan Medical Association = Taiwan yi zhi. vol 96. issue 8. 1997-09-25. PMID:9290269. |
steady-state plasma concentrations of clozapine and its metabolites, desmethylclozapine and clozapine-n-oxide, were measured in 162 taiwanese patients with refractory schizophrenia. |
1997-09-25 |
2023-08-12 |
Not clear |
| P Monteleone, M Fabrazzo, A Tortorella, M Ma. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry research. vol 71. issue 1. 1997-09-23. PMID:9247977. |
plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. |
1997-09-23 |
2023-08-12 |
human |
| C J Hong, J Y Chen, H J Chiu, C B Si. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. International clinical psychopharmacology. vol 12. issue 3. 1997-09-22. PMID:9248867. |
a double-blind comparative study of clozapine versus chlorpromazine on chinese patients with treatment-refractory schizophrenia. |
1997-09-22 |
2023-08-12 |
Not clear |
| C J Hong, J Y Chen, H J Chiu, C B Si. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. International clinical psychopharmacology. vol 12. issue 3. 1997-09-22. PMID:9248867. |
clozapine has been shown to have superior effectiveness compared with classic neuroleptics in treating refractory schizophrenia in caucasians, but its efficacy and safety in chinese have not been adequately studied. |
1997-09-22 |
2023-08-12 |
Not clear |